PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics, Inc. is a biotechnology company, which specializes in the discovery and development of therapeutics to treat central nervous system disorders. It offers the PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

$1.65  +0.02 (1.23%)
As of 12/06/2021 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  12/18/1996
Outstanding shares:  16,955,817
Average volume:  252,342
Market cap:   $27,637,982
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.70
PS ratio:   0.00
Return on equity:   -40.08%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy